

Dyslipidemia jako ważny czynnik ryzyka chorób sercowo-naczyniowych. Metody postępowania

prof. dr hab. med. Barbara Cybulska, prof. dr hab. med. Wiktor B. Szostak

1. Graham I., Atar D., Borch-Johnsen K. i wsp.: European Guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur. J. Cardiovasc. Prev. Rehab.* 2007; 14 supl 2: S11-S113.
2. Austin M.A., King M.C., Vranizan K.M. i wsp.: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. *Circulation* 1990; 82: 495-506.
3. Szostak W.B., Cybulska B.: Żywnie w hiperlipidemii. W: Żywnie człowieka zdrowego i chorego. T. 2. Pod red. J.Hasika, J.Gawęckiego. PWN, Warszawa 2000.
4. Kiss R.S., Kavaslar N., Okuhira K. i wsp.: Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. *Arterioscler. Thromb. Vasc. Biol.* 2007; 27: 1139-1145.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002; 106: 3143-3421.
6. Szostak W.B., Marianowski L., Kłosiewicz-Latoszek L., Nowicka G.: HDL-chol, apo B, total cholesterol (TC) and triglycerides in umbilical cord blood. *Żyw. Człow. Metab.*, 1984; 11: 231-236.
7. American Diabetes Association. Executive Summary. Standards of Medical Care in Diabetes – 2008. *Diabetes Care* 2008; 30 supl. 1: S1-S11.
8. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę, 2008. Stanowisko Polskiego Towarzystwa Diabetologicznego. *Diabet. Prakt.* 2008; 9 supl. A: A1-A48.
9. Kinsell L.W., Partridge J., Boling L. i wsp.: Dietary modification of serum cholesterol and phospholipid levels. *J. Clin. Endocrinol.* 1952; 12: 909-913.
10. Keys A., Anderson J.T., Grande F.: Prediction of serum cholesterol responses of men to changes in fats in the diet. *Lancet* 1957; 2: 959-966.
11. Mensink R.P., Zock P.L., Kester A.D.M. i wsp.: Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and

- apolipoproteins: a meta-analysis of 60 controlled trials. *Am. J. Clin. Nutr.* 2003; 77: 1146-55.
12. Kunachowicz H., Nadolna I., Przygoda B. i wsp.: Tabele składu i wartości odżywczych żywności. PZWL, Warszawa 2005.
 13. Mitrou P.N., Kipnis V., Thiebaut A.C.M., i wsp.: Mediterranean dietary pattern and prediction of all-cause mortality in a US population. *Arch. Intern. Med.* 2007; 167: 2461-2468.
 14. Bays H., Stein E.S.: Pharmacotherapy for dyslipidemia: current therapies and future agents. *Expert Opin. Pharmacother.* 2003; 4: 1991-1938.
 15. tabela 3. Jones P.H., Davidson M.H.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). *Am. J. Cardiol.* 2003; 92: 152-160.
 16. Farmer J.A.: Handbook of cholesterol management . Sec. Ed. Current Medicine Group Ltd, London 2007.
 17. Barter P., Rye K.A.: High density lipoprotein cholesterol: The new target. Third Ed. Sherborne Gibbs Limited, Birmingham 2007.
 18. Feher M.D., Richmond W.: Lipidy i zaburzenia lipidowe. Wyd. Via Medica, Gdańsk 2002.
 19. Ballantyne C.M., Abate N., Yuan Z. i wsp. :Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) study. *Am. Heart J.* 2005; 149: 464-473.
 20. Grundy S.M., Cleeman J.I., Merz C.N. i wsp. : For the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *Circulation* 2004; 110: 227-239.
 21. Kłosiewicz-Latoszek L., Szostak W.B., Grzybowska B. i wsp.: Hiperlipidemia mieszana. Terapia skojarzona fenofibratem mikronizowanym z simwastatyną, a monoterapia. *Kardiol. Pol.* 2004; 6: 573-577.
 22. Kasaniemi A.: Cholesterol absorption inhibitors in the treatment of hyperlipidemia: clinical outcomes in large clinical trials. *Fundam. Clin.Pharmacol.* 2007; 21, supl 2: 29-30.

Epidemiologia zaburzeń lipidowych w Polsce.

dr med. Tomasz Zdrojewski,

1. *Rocznik Statystyczny Rzeczypospolitej Polskiej 2007*. Warszawa: Główny Urząd Statystyczny, 2007.
2. Narodowy program profilaktyki i leczenia chorób układu sercowo-naczyniowego POLKARD 2003-2005. *Kardiol. Pol* 2003(59):535-544.
3. Yusuf S, Hawken S, Ounpuu S i wsp. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364(9438):937-52.
4. Zdrojewski T, Bandosz P, Szpakowski P i wsp. Rozpowszechnienie głównych czynników ryzyka chorób układu sercowo-naczyniowego w Polsce. Wyniki badania NATPOL PLUS. *Kardiol. Pol* 2004;61(supl. IV):IV1-IV26.
5. Rywik S, Kupść W, Piotrowski W i wsp. Wieloośrodkowe ogólnopolskie badanie stanu zdrowia ludności – projekt WOBASZ. Założenia metodyczne oraz logistyka. *Kardiol. Pol.* 2005;63(6, supl. 4):S1-S4.
6. Broda G, Rywik S. Wieloośrodkowe ogólnopolskie badanie stanu zdrowia ludności – projekt WOBASZ. Zdefiniowanie problemu oraz cele badania. *Kardiol. Pol.* 2005;63(6, supl. 4):S1-S4.
7. Filipiak K, Pietrasik A, Starczewska M i wsp. Wieloośrodkowy Ogólnopolski System Monitorowania Standardu Podstawowej Opieki Kardiologicznej w Warunkach Podstawowej Opieki zdrowotnej (POLKARD-SPOK): metody przyjęte podczas realizacji programu. *Kardiol. Pol.* 2006;64(8):S167-S171.
8. Wizner B, Dubiel S, Zdrojewski T i wsp. Ogólnopolski program oceny diagnostyki, leczenia i kosztów u chorych z niewydolnością serca w losowo wybranych jednostkach leczenia otwartego i zamkniętego na poziomie podstawowym, wojewódzkim i specjalistycznym. *Folia Cardiol.* 2006;13(1):73-81.
9. Gaining health. The European Strategy for the Prevention and Control of Noncommunicable Diseases. 2006:1-46.
10. Lim SS, Gaziano TA, Gakidou E i wsp. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. *Lancet* 2007;370(9604):2054-62.

11. Abegunde DO, Mathers CD, Adam T, Ortegón M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. *Lancet* 2007;370(9603):1929-38.
12. *Sprawozdanie z działalności Narodowego Funduszu Zdrowia za 2007 rok*. Warszawa: Narodowy Fundusz Zdrowia, 2008.

Genetyczne uwarunkowania zaburzeń lipidowych.

prof. dr hab. med. Maciej T. Małecki, prof. dr hab. med. Dariusz Moczulski

1. Austin MA, Hutter CM, Zimmern RL, Humphries SE: Familial hypercholesterolemia and coronary heart disease: a HuGE association review. *Am J Epidemiol* 2004; 160: 421-429.
2. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ: Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. *J Lipid Res* 1990; 31: 1337-1349.
3. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villegier L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet* 2003; 34: 154-156
4. Garcia C.K., Wilund K., Arca M. i wsp.: Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. *Science* 2001; 292: 1394-1398.
5. Berge K.E., Tian H., Graf G.A. i wsp.: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. *Science* 2000; 290: 1771-1775.
6. Altmann S.W., Davis H.R. Jr, Zhu L.J. i wsp.: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. *Science* 2004; 303: 1201-1204.
7. Pullinger C.R., Eng C., Salen G. i wsp.: Human cholesterol 7 α -hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. *J Clin Invest* 2002; 110: 109-117.
8. Smelt AH, de Beer F: Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. *Semin Vasc Med* 2004, 4:249-57.

9. Singaraja R.R., Fievét C., Castro G. i wsp.: Increased ABCA1 activity protects against atherosclerosis. *J Clin Invest* 2002; 110: 35-42.
10. Nissen S.E., Tsunoda T., Tuzcu E.M. i wsp.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. *JAMA* 2003; 290: 2292-2300.
11. Pajukanta P., Lilja H.E., Sinsheimer J.S. I wsp.: Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). *Nat Genet* 2004 36:371-6.

HDL – lipoproteiny o wysokiej gęstości. Hipoalfalipoproteinemia

Doc. dr hab. Grażyna Nowicka

1. Miller NE, Thelle DS, Forde OH, Mjos OD. The Thomso Heart Study. High density lipoprotein and coronary heart disease: a prospective case-control study. *lancet* 1977, 1:965
2. Gordon DY, Probstfield JL, Garrison RJ, i wsp. High density lipoproteins cholesterol and cardiovascular disease. Four Prospective American Studies. *Circulation* 1989, 78: 8
3. Nowicka G. Lipoproteiny o wysokiej gęstości i ich potencjalne działanie przeciwmiażdżycowe. *Farm Pol* 1998, 54: 153
4. Nowicka G. HDL - lipoproteiny o wysokiej gęstości. Teoria a praktyka kliniczna. *Kardiol Pol* 2002, 57: 150
5. de-Goma E, de-Goma R, Rader D. Beyond high density lipoprotein cholesterol levels evaluating high density lipoprotein function as influenced by novel therapeutic approaches. *J Am Coll Cardiol* 2008, 51: 2199
6. Nowicka G. Zaburzenia syntezy i katabolizmu HDL. *Czynniki Ryzyka* 1995, 2(8): 25
7. Frikke-Schmidt R, Nordestgaard B, Jensen G, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. *J Clin Invest* 2004, 114:1343
8. Kiss RS, Kavaslar N, Okuira K i wsp. Genetic etiology of isolated low HDL syndrome. Incidence and heterogeneity of efflux defects. *Arterioscler Thromb vasc Biol* 2007, 27: 1139
9. Nowicka G. Control and clinical significance of high density lipoproteins. *Czynniki Ryzyka*, 1999, supl.6: 24

10. Nowicka G, Cybulska B. Patogeneza i diagnostyka zaburzeń lipidowych w cukrzycy. W „Cukrzyca”, red. J.Sieradzki; Via Medica, Gdańsk 2006, tom 2, str 993
11. McTagger F, Jones P. Effects of statins on high density lipoproteins: a potential contribution to cardiovascular benefit. *Cardiovasc Drug Ther* 2008, 22: 321
12. Nowicka G, Jarosz A. LpAI in HDL subpopulations: serum levels in men and women with coronary heart disease and changes under hypolipemic therapy. *Clin Chim Acta* 2001, 306: 43-49
13. Kastelein JJ, van Leuven SI, Gurgess L, et al. Effect of torcetrapib on carotid atherosclerosis. *N Engl J Med* 2007, 356: 1620
14. Taylor A.J. Evidence to support aggressive management of high density lipoprotein cholesterol: implications of recent imaging trials. *Am J Cardiol* 2008, 101[suppl]: 36B
15. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries: the INTERHEART study. *Lancet* 2004, 364:937
16. van der Steeg W, Holme I, Boekholdt M i wsp. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein AI: significance for cardiovascular risk. The IDEAL and EPIC-Norfolk Studies. *J Am Coll cardiol* 2008, 51; 634
17. Tanigawa JT, Billheimer J, Tohyama Y, et al. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. *Circulation* 2007, 116:1267
18. Zhong S, Sharo DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in cholesteryl ester transfer protein despite increased HDL levels. *J Clin Invest* 1996, 97:2917

Niefarmakologiczne leczenie dyslipidemii

Dr hab. n. med. Małgorzata Kozłowska-Wojciechowska

1. Diet, nutrition and prevention of chronic disease. Report of the Joint WHO/FAO expert consultation. Geneva 2002.
2. Schaefer E.J.: Lipoproteins, nutrition, and heart disease. *Am. J. Clin. Nutr.* 2002; 75: 191.

3. Ornish D.: Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280: 2001-2007
4. Poli A, Marangoni F, Paoletti R, et al.: Non-pharmacological control of plasma cholesterol levels. Nutr Metab Cardiovasc Dis. 2008;18(2):S1-16.
5. Bonow R.O.: Primary Prevention of Cardiovascular Disease. Circulation. 2002, 106, 3140-3144
6. Grundy S.M.: Prevention Conference VI: Diabetes and Cardiovascular Disease. Writing Group IV: Lifestyle and Medical Management of Risk Factors. Circulation. 2002, 105, 153-160.
7. Carson JA. Nutrition therapy for dyslipidemia. Curr Diab Rep. 2003;3(5):397-403.
8. Trichopoulos D, Lagiou P.: Dietary patterns and mortality. Br J Nutr. 2001, 85, 133-134.
9. Kozłowska-Wojciechowska M.: Mechanizm hipotensyjnego oddziaływania kwasów omega-3. Kardioprofil 2007, 5: 345-351.
10. Villegas R, Kearney PM, Perry IJ. The cumulative effect of core lifestyle behaviours on the prevalence of hypertension and dyslipidemia. BMC Public Health. 2008;8:210-218.

Przeciwpalne działanie fibratów wzmacnia ich rolę w monoterapii dylipidemii.

prof. dr hab. n. farm. Marek Naruszewicz

1. [Marx N, Sukhova GK, Collins T, Libby P, Plutzky J.](#) PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125-31.
2. [Delerive P, Gervois P, Fruchart JC, Staels B.](#) Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. [J Biol Chem.](#) 2000;275:36703-7
3. [Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK.](#) Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care. 2005;28:1419-24.

4. [Okopień B, Krysiak R, Herman ZS](#). Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. *J Clin Endocrinol Metab.* 2006;91:1770-8.
5. [Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B](#). Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. *Arterioscler Thromb Vasc Biol.* 2006;26:977-86.
6. [Rosenson RS, Huskin AL, Wolff DA, Helenowski IB, Rademaker AW](#). Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. *Atherosclerosis.* 2008;198:381-8.

Nowe leki w terapii hipolipemizującej

prof. dr hab. med. Piotr Podolec

dr n. med. Grzegorz Kopec

1. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. *Expert Rev Cardiovasc Ther.* 2008;6(4):447-470.
2. Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, Davies JP, Nilsson LM, Yu L. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. *J Clin Invest.* 2007;117(7):1968-1978.
3. Rossebo AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, Gerds E, Gohlke-Barwolf C, Holme I, Kesaniemi VA, Malbecq W, Nienaber C, Ray S, Skjaerpe T, Wachtell K, Willenheimer R. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. *Am J Cardiol.* 2007;99(7):970-973.
4. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). *Kidney Int Suppl.* 2003(84):S207-210.
5. Musunuru K, Blumenthal RS. The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: a return to first principles. *Clin Cardiol.* 2008;31(6):288-290.
6. Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. *Am J Clin Nutr.* 2008;87(6):1981S-1990S.
7. Ness AR, Hughes J, Elwood PC, Whitley E, Smith GD, Burr ML. The long-term effect of dietary advice in men with coronary disease: follow-up of the Diet and Reinfarction trial (DART). *Eur J Clin Nutr.* 2002;56(6):512-518.

8. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. *Circulation*. 2002;105(16):1897-1903.
9. Yokoyama M, Origasa H. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). *Am Heart J*. 2003;146(4):613-620.
10. Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J, Kang JX, Cox B, Zhang H, Schoenfeld D. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. *Circulation*. 2005;112(18):2762-2768.
11. Brouwer IA, Zock PL, Camm AJ, Bocker D, Hauer RN, Wever EF, Dullemeijer C, Ronden JE, Katan MB, Lubinski A, Buschler H, Schouten EG. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. *JAMA*. 2006;295(22):2613-2619.
12. Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, McClelland J, Cook J, MacMurdy K, Swenson R, Connor SL, Gerhard G, Kraemer DF, Oseran D, Marchant C, Calhoun D, Shnider R, McAnulty J. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. *JAMA*. 2005;293(23):2884-2891.
13. Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, Meo A, Pandozi C, Staibano M, Santini M. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. *J Am Coll Cardiol*. 2005;45(10):1723-1728.
14. Smith SC, Jr., Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update:

- endorsed by the National Heart, Lung, and Blood Institute. *Circulation*. 2006;113(19):2363-2372.
15. Klosiewicz-Latoszek L, Szostak WB, Podolec P, Kopec G, Pajak A, Kozek E, Naruszewicz M, Stanczyk J, Opala G, Windak A, Zdrojewski T, Drygas W, Klupa T, Undas A, Czarnecka D, Sieradzki J. Polish Forum for Prevention Guidelines on Diet. *Kardiol Pol*. 2008;66(7):812-814.
 16. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FW, Wijns W. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J*. 2003;24(1):28-66.

Złożona terapia hipolipemizująca

prof. dr hab. med. Longina Klosiewicz-Latoszek

1. Deedwania P., Barter P., Carmena R., et. al.: for the Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome. Analysis of the Treating to New Targets study. *Lancet*, 2006; 368: 919-928.
2. Fazio S.: Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease a role for combination fibrate therapy. *Clin. Ther.* 2008, 30, 2, 294-306.
3. Cannon C.P., Braunwald E., McCabe C.H., et. al.: for the Pravastatin or Atorvastatin Evaluation and Infection 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes, *N. Engl. J. Med.* 2004; 350: 1495-1504.
4. Alsheikh-Ali A.A., Lin J-L., Abourjaily P., et. al.: Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. *Am. J. Cardiol.*, 2007, 100, 1499-1501.
5. Grundy S.M., Cleeman J.I., Bairey Merz C.N., et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines *Circulation*, 2004, 116, 227-39.

6. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur. Heart J.* 2007, 28, 2375-2412.
7. Kastelein J.J.P., Akdim F., Stres E.S.G., et. al. for the ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. *N. Engl. J. Med.* 2008, 358: 1431-43.
8. O’Riordam M.: Vytorin misses primary endpoint in SEAS study. <http://www.medscape.com/viewarticle/577850>.
9. Grundy S.M., Vega G.L., Yuan Z. et al.: Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). *Am. J. Cardiol.*, 2005, 95(4), 462-8.
10. Kłosiewicz-Latoszek L., Szostak W.B., Grzybowska B. i wsp.: Hiperlipidemia mieszana. Terapia skojarzona fenofibratem mikronizowanym z simwastatyną a monoterapia. *Kardiologia Polska*, 2004; 6, 573-77.
11. The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study randomized controlled trial). *Lancet*, 2005; 366: 1849-61.
12. Brown B.G., Zhao X.Q., Chait A., et. al. : Simvastatin and niacin, antioxidant vitamins, or the combination for prevention of coronary disease. *N. Engl. J. Med.*, 2001, 345, 1583-92.
13. Taylor A.J., Sullenberger L.E., Lee H.J., et. al.: Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER)²: A double-blind, placebo-controlled study of extended-release niacin in atherosclerosis progression in secondary prevention patients treated with statins. *Circulation*, 2006, 110, 3512-17.
14. Lai E., Delepeleire I., Crumley T.M., et. al. : Suppression of niacin-induced vasodilatation with an antagonist to prostaglandin D₂ receptor subtype 1. *Clin. Pharmacol. Ther.*, 2007, 81, 849-57.
15. Kris-Etherton P.H., Harris W.S., Appel L.J. for the Nutrition Committee: AHA Scientific Statement, Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation*, 2002, 106, 2747-57.
16. Yokoyama M., Origasa H., Matsuzaki M., et. al.: Effects of eicosapentaenic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized openlabel, blinded endpoint analysis. *Lancet*, 2007, 369, 1090-98.

17. Davidson M.H., Stein E.A., Bays H.E., et. al. for the COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators: Efficacy and tolerability of adding prescription Omega 3 fatty acids 4g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled Study. *Clin. Ther.*, 2007, 29, 7, 1354-67.
18. Farnier M.: Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia? *Expert Opin. Pharmacother.* 2007, 8(9), 1345-52.
19. Farnier M., Roth E., Gil-Extremera B., et. al. : Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. *Am. Heart J.*, 2007, 153 (2), 335 e 1-8.
20. Guyton J.R., Brown B.G., Fazio S., et. al.: Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. *J. Am. Coll. Cardiol.*, 2008, 51 (16), 1564-72.

Bezpieczeństwo stosowania statyn i fibratów–uwagi praktyczne
prof. nadzw. dr hab. med. Krzysztof J. Filipiak

1. Filipiak KJ, Grabowski M. Działania niepożądane statyn i fibratów – implikacje i uwagi praktyczne dla terapii skojarzonej tymi grupami leków. *Kardioprofil 2004; 4: 7-11.*
2. Filipiak KJ, Opolski G (red.). Statyny – zarys farmakologii klinicznej. Wyd. Biblioteka Lekarza Praktyka, Warszawa, 2002.

Postępowanie w dyslipidemii u dzieci. Kiedy diagnozować i jak leczyć?

dr n. med. Dorota Szostak-Węgierek

1. Berenson GS, Srinivasan SR, Bao W. i wsp. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. *NEJM* 1998, 338: 1650-6.
2. Eggen DA, Solberg LA. Variation of atherosclerosis with age. *Labor Invest* 1968,18,571.
3. Urbina EM, Srinivasan SR, Tang R, i wsp. Impact of multiple coronary risk factors on the intima-media thickness of different segments of carotid artery in healthy young adults (the Bogalusa Heart Study). *Am J Cardiol* 2002,90:953-58.
4. McGill HC, McMahan CA, Herderick EE i wsp. Origin of atherosclerosis in childhood and adolescence. *Am J Clin Nutr* 2000,72(5 Suppl): 1307S-1315S.

5. Szostak-Węgierek D, Cybulska B: Zespół metaboliczny u dzieci. W: Miażdżyca u dzieci i młodzieży. Red. Urban M. Cornetis, Wrocław 2007, wydanie I, strony 221-236.
6. Szostak-Węgierek D: Zespół metaboliczny u dzieci i młodzieży jako wyzwanie dla zdrowia publicznego. *Problemy Higieny i Epidemiologii* 2008, 89(1), 21-29.
7. Dietary Recommendations for Children and Adolescents: A Guide for Practitioners: Consensus Statement From the American Heart Association Endorsed by American Academy of Pediatrics. *Circulation* 2005,112:2061-75.
8. Zimmet P, Alberti G, Kaufman F i wsp. The metabolic syndrome in children and adolescents. *The Lancet* 2007; 369: 2059-61.
9. Kavey REW, Allada V, Daniels SR i wsp. Cardiovascular risk reduction in high-risk pediatric patients. A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. Endorsed by the American Academy of Pediatrics. *Circulation* 2006,114,2710-38.
10. Barlow S, Dietz W. Obesity evaluation and treatment: expert committee recommendations. *Pediatrics* 1998,102,e29.
11. Hoffman RP, Stumbo PJ, Janz KF. Altered insulin resistance is associated with increased dietary weight loss in obese children. *Hormone Research* 1995,44,17-22.
12. ADA consensus development conference on insulin resistance. *Diabetes care* 1998, 21,310-14.
13. Andersen LB, Harro M, Sardinha LB i wsp. Physical activity and clustered cardiovascular risk in children: a cross-sectional study (The European Youth Heart Study). *The Lancet* 2006,368,299-304.
14. McCrindle BW, Urbina EM, Dennison BA i wsp. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association, Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council of Cardiovascular Nursing. *Circulation* 2007,115.1948-67.
15. McCrindle BW, Manliot C. Elevated atherogenic lipoproteins in childhood: risk, prevention, and treatment. *J Clin Lipidology* 2008,2,138-146.
16. Browne B, Vasquez S. Pediatric dyslipidemias: prescription medication efficacy and safety. *J Clin Lipidology* 2008, 2, 189-210.

Leczenie zaburzeń lipidowych w otyłości i zespole metabolicznym

Dr n med. Andrzej Folga, prof. nadzw. dr hab. med. Artur Mamcarz

1. Jolliffe CJ, Janssen I. Vascular risks and management of obesity in children and adolescents. *Vasc Health Risk Manag.* 2006; 2(2): 171-187.
2. Friedlander AH, Weinreb J, Friedlander I. Metabolic syndrome: pathogenesis, medical care and dental implications. *J Am Dent Assoc.* 2007; 138(2): 179-187.
3. Kashyap SR, Defronzo RA. The insulin resistance syndrome: physiological considerations. *Diab Vasc Dis Res.* 2007; 4(1): 13-19.
4. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* 1988; 37: 1595-1607.
5. International Diabetes Federation. Worldwide definition of the metabolic syndrome. Available at: http://www.ifd.org/webdata/docs/IDF_Metasyndrome_definition.pdf. Accessed August 24, 2005.
6. Grundy SM, Cleeman JI, Merz CN. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Coordinating Committee of the National Cholesterol Education Program. *J Am Coll Cardiol.* 2004; 44(3): 720-732.
7. Day C. Metabolic syndrome, or What you will: definitions and epidemiology. *Diab Vasc Dis Res.* 2007; 4(1): 32-38.
8. Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. *Cardiol Rev.* 2005; 13(6): 322-327.
9. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. *J Clin Endocrinol Metab.* 2007; 92(2): 399-404.
10. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. *CMAJ.* 2007; 176(8): 1113-1120.
11. Tenenbaum A, Fisman EZ, Motro M. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. *Cardiovasc Diabetol.* 2006; 5: 20.
12. Grundy SM, Vega GL, Yuan Z. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). *Am J Cardiol.* 2005; 95(4): 462-468.

13. Keech A, Simes RJ, Barter P, FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet* 2005; 366(9500):1849-1861.
14. Keech AC, Mitchell P, Summanen PA. FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. *Lancet* 2007; 370(9600): 1687-1697.

Dr n. med. Elżbieta Kozek

Jak postępować w dyslipidemii u chorego na cukrzycę?

1. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) *BMJ*. 1998;316:823-8.
2. Lehto S, Rönnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. *Diabetes*. 1997; 46:1354-9
3. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. *E Heart J*, 2007; 9, suppl. C
4. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę. 2008; 9, suppl. A
5. ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. *Am J Cardiol*. 2007;99:21i-33i.
6. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med*. 2008;358:580-91.

Specyfika leczenia dyslipidemii w przewlekłej chorobie nerek.

Andrzej Kraśniak, Andrzej Radziszewski, Władysław Sułowicz

1. Dogra G. K., Herrmann S., Irish A. B. et al.: Insulin resistance, dyslipidaemia and endothelial function in nephrotic syndrome. *Nephrol. Dial. Transplant.*, 2002; 17: 2220-2225.
2. Mittal B. V., Alexander M. P., Rennke H. G., Singh A. K.: Atheroembolic renal disease: a silent masquerader. *Kidney Int.*, 2008; 73: 126-130.
3. Efstratiadis G., Tziomalos K., Mikhailidis D. P. et al.: Atherogenesis in renal patients: a model of vascular disease? *Curr. Vasc. Pharmacol.*, 2008; 6: 93-107.
4. Cases A., Coll E.: Dyslipidemia and the progression of renal disease in chronic renal failure patients. *Kidney Int.*, 2005; 68 (Suppl. 99): 87-93.
5. Rutkowski B., Chmielewski M., Zdrojewski Z.: Znaczenie leczenia hipolipemizującego w nefroprotekcji. [w:] *Nefroprotekcja. Podstawy patofizjologiczne i standardy postępowania terapeutycznego.* red. Rutkowski B., Czekański S., Myśliwiec M. wyd. Czelej Lublin 2006; 179.
6. Schibata S., Nagase M., Fujita T.: Fluvastatin ameliorates podocytes injury in proteinuric rats via modulation of excessive rho signaling. *J. Am. Soc. Nephrol.*, 2006; 17: 754-764.
7. D'Amico G.: Statins and renal diseases: from primary prevention to renal replacement therapy. *J. Am. Soc. Nephrol.*, 2006; 17: 148-152.
8. Gianella A., Nobili E., Abbate M. et al.: Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. *Am. J. Pathol.*, 2007; 170: 1165-1177.
9. Tonelli M., Moye L., Sacks F. M. et al.: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. *J. Am. Soc. Nephrol.*, 2003; 14: 1605-1613.
10. Athyros V. G., Mikhailidis D. P., Papageorgiou A. A. et al.: The effects of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. *J. Clin. Pathol.*, 2004; 57: 728-734.
11. Douglas K., O'Malley P. G., Jackson J. L.: Meta-analysis: the effect of statins on albuminuria. *Ann. Intern. Med.*, 2006; 145: 117-124.
12. Tonelli M.: Do statins protect the kidney as well as the heart? *Nephrol. Dial. Transplant.*, 2006; 21: 3005-3006.
13. Atthobari J., Brantsma A. H., Gansevoort R. T. et al.: The effect of statin on urinary albumin excretion and glomerular filtration rate: results from both a randomized

clinical trial and an observational cohort study. *Nephrol. Dial. Transplant.*, 2006; 21: 3106-3114.

14. Agarwal R.: Statin induced proteinuria: renal injury or renoprotection? *J. Am. Soc. Nephrol.*, 2004; 15: 2502-2503.